Waldman Lawrence 4

What Happened Lawrence Waldman, a director of Apyx Medical Corp (APYX), received a derivative award on 2026-06-11: a grant of options covering 50,000 shares. The reported price/exercise in the filing is $0.00 (the Form 4 records the transaction value as $0). This is an equity award (not an open-market buy or sale) and is typically a compensation/retention grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-06-11; Filing date: 2026-06-15 (Form 4).
• Security/amount: Grant of options for 50,000 shares; reported price/exercise: $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award is a stock option that vests ratably over 12 months and becomes fully vested and exercisable on the first anniversary of the grant (see footnote F1).
• Timeliness: Filing appears timely (filed on 6/15/2026, within the standard 2 business days after a 6/11/2026 transaction).

Context This is a derivative compensation grant (stock option award) to a director. Such awards are common as part of director compensation and do not itself indicate an immediate purchase or sale of shares. The filing shows the option terms and vesting schedule; there is no indication the options were exercised or shares sold.